Journal Home
Search for

Volume 21, Issue 2, Pages 127-134 (April 2010)


View previous. 8 of 18 View next.

Impact of tumor microenvironment on oncolytic viral therapy

Jeffrey Wojtonab, Balveen KauraCorresponding Author Informationemail address

published online 20 April 2010.

Abstract 

Interactions between tumor cells and their microenvironment have been shown to play a very significant role in the initiation, progression, and invasiveness of cancer. These tumor–stromal interactions are capable of altering the delivery and effectiveness of therapeutics into the tumor and are also known to influence future resistance and re-growth after treatment. Here we review recent advances in the understanding of the tumor microenvironment and its response to oncolytic viral therapy. The multifaceted environmental response to viral therapy can influence viral infection, replication, and propagation within the tumor. Recent studies have unveiled the complicated temporal changes in the tumor vasculature post-oncolytic virus (OV) treatment, and their impact on tumor biology. Similarly, the secreted extracellular matrix in solid tumors can affect both infection and spread of the therapeutic virus. Together, these complex changes in the tumor microenvironment also modulate the activation of the innate antiviral host immune response, leading to quick and efficient viral clearance. In order to combat these detrimental responses, viruses have been combined with pharmacological adjuvants and “armed” with therapeutic genes in order to suppress the pernicious environmental conditions following therapy. In this review we will discuss the impact of the tumor environment on viral therapy and examine some of the recent literature investigating methods of modulating this environment to enhance oncolysis.

a Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, OH, United States

b Neuroscience Graduate Studies Program, The Ohio State University Medical Center, Columbus, OH 43210, United States

Corresponding Author InformationCorresponding author at: Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University, 385-D OSUCCC, 410 West 12th Avenue, Columbus, OH 43210, United States. Tel.: +1 614 292 3984; fax: +1 614 688 4882.

PII: S1359-6101(10)00025-0

doi:10.1016/j.cytogfr.2010.02.014


View previous. 8 of 18 View next.